Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genome Diagnostics Laboratory, |
RCV002294699 | SCV002587610 | uncertain significance | Atypical hemolytic-uremic syndrome | 2022-07-08 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003101703 | SCV003292134 | uncertain significance | not provided | 2023-12-14 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine, which is neutral and non-polar, with histidine, which is basic and polar, at codon 4 of the CFI protein (p.Leu4His). This variant is present in population databases (rs374141986, gnomAD 0.05%). This missense change has been observed in individual(s) with secondary hemolytic uremic syndrome (PMID: 30982675). ClinVar contains an entry for this variant (Variation ID: 1712444). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CFI protein function with a negative predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Mayo Clinic Laboratories, |
RCV003101703 | SCV004227016 | uncertain significance | not provided | 2022-04-11 | criteria provided, single submitter | clinical testing | BP4 |